Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms

SHANGHAI and GAITHERSBURG, Md., July 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the signing of two new collaborations with emerging biote...

2021-07-09 20:00 30619

Sequanta and Mission Bio announce strategic partnership

SHANGHAI, July 8, 2021 /PRNewswire/ -- Sequanta Technologies Co., Ltd. ("Sequanta") and Mission Bio. ("Mission Bio") are pleased to announce that they have entered into a strategic partnership, providing high-quality single-cell sequence services using Mission Bio's products to customers in mainl...

2021-07-09 15:44 2393

Innovent Announces NMPA Acceptance of New Drug Application for the FGFR1/2/3 Inhibitor (Pemigatinib) for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement

SAN FRANCISCO, and SUZHOU, China, July 9, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-07-09 08:00 24025

COVID pandemic heightens a lack of confidence amongst the public about which medicines to take and how to use them

New campaign, Let's treat it right, launches as online searches for self-care surge globally[1], as people take more responsibility for their everyday health. NYON, Switzerland, July 8, 2021 /PRNewswire/ -- Today sees the launch of Let's treat it right, a major new health education campaign d...

2021-07-08 16:00 2084

COVID pandemic heightens a lack of confidence amongst the public about which medicines to take and how to use them

Nippon Express (India) Newly Acquires GDP Certification at Three Locations

TOKYO, July 8, 2021 /PRNewswire/ -- Nippon Express (India) Private Limited (hereinafter "NE India"), a local subsidiary of Nippon Express Co., Ltd., obtained Good Distribution Practice (GDP) certification in April for its temperature-controlled hubs inDelhi, Mumbai and Ahmedabad, evidencing the ...

2021-07-08 15:00 1783

BioShin Expands Senior Leadership Team: Sarah Lu Joins BioShin as Chief Medical Officer, Mary Ma Joins BioShin as Chief Commercial Officer

SHANGHAI, July 8, 2021 /PRNewswire/ -- BioShin Limited today announced the appointment of Dr.Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial Officer. Sarah will play a critical role in BioShin's clinical development of pipeline products inAsia-Pacific markets,...

2021-07-08 12:01 2715

Otsuka Signs Three-Year Collaboration with Holmusk to Enhance Digital Health and Data Analytics for Global Behavioral Health Programs

PRINCETON, N.J., July 8, 2021 /PRNewswire/ -- Otsuka Pharmaceutical Development & Commercialization, Inc. ("Otsuka"), announces today that it has entered a three-year collaboration with Holmusk Inc. ("Holmusk"), a global data science and digital health company building the world's largest real-wo...

2021-07-08 00:56 3709

dMed-Clinipace Announces Completion of US$50 Million Series C+ Financing from New Investors

SHANGHAI and MORRISVILLE, N.C., July 7, 2021 /PRNewswire/ -- dMed-Clinipace, the global full-service Clinical Contract Research Organization (CRO), announced today the recent successful completion of aUS$50 million Series C+ financing with participation from a group of new, leading international ...

2021-07-07 20:00 4927

Biocytogen/Eucure Biopharma's CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA

BOSTON and BEIJING, July 7, 2021 /PRNewswire/ -- Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing antibody drugs with independent intellectual property rights, announced that the U.S. Food and Drug Administration (FDA) has approved two...

2021-07-07 16:41 3217

CStone announces China NMPA acceptance of IND application for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody-based molecule, marking further expansion of its Pipeline 2.0 strategy

SUZHOU, China, July 7, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the investigational new ...

2021-07-07 08:05 4032

New Cancer Treatment For Australian Dogs With APVMA Approval Of Qbiotics' Stelfonta®

* STELFONTA® (tigilanol tiglate) is now approved by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment of canine non-metastatic mast cell tumours (MCT). * APVMA approval follows marketing authorisation (registration) and launch of STELFONTA® in the major co...

2021-07-07 06:34 2476

New Cancer Treatment For Australian Dogs With APVMA Approval Of Qbiotics' Stelfonta®

Transcenta Announces NMPA Acceptance of IND Application of its Anti-Sclerostin Monoclonal Antibody TST002

SUZHOU, China, July 6, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announces that NMPA has accepted IND applica...

2021-07-06 21:36 2262

Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis

* Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, substantial and persistent clinical improvement over placebo * Favorable safety and tolerability profile with no serious adverse events (SAEs) and no adverse events (AEs) leading to discontinuation * Strong IgG reductio...

2021-07-06 21:06 18704

Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD

ADELAIDE, Australia, July 6, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in p...

2021-07-06 18:00 17894

Seegene announces partnership with Bio-Rad to develop diagnostic testing products for the U.S. Market

* Seegene announces partnership with Bio-Rad for the development and commercialization of infectious disease molecular diagnostic products * Diagnostic tests designed for the pandemic and the post-pandemic era with high multiplex technology * A significant step forward for Seegene in expandi...

2021-07-06 18:00 2585

Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate

* SPECTRA enrolled over 29,000 adult and elderly participants across four continents achieving high ethnic diversity and robust dataset of circulating strains * Release of vaccine efficacy data anticipated in Q3 2021 and will include sequencing data of SARS-CoV-2 variants of concern and varia...

2021-07-06 14:00 3614

Bora Group announce the rebranding of Yuta Health to Bora Health

TAIPEI, July 6, 2021 /PRNewswire/ -- Leading Taiwan-based contract development and manufacturing organization (CDMO) Bora Group today announced a name change for its subsidiary, currently Yuta Health, to Bora Health Inc. as part of an overall plan to integrate its distribution operations and b...

2021-07-06 13:31 3481

Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China

SAN FRANCISCO and SUZHOU, China, July 6, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...

2021-07-06 08:00 5774

South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology

DAEJEON, South Korea and CASTRES, France, July 6, 2021 /PRNewswire/ -- The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights toPierre Fabre to develop and commercialize a family of hum...

2021-07-06 07:00 5731

Octapharma's ongoing dedication to improving the lives of people with haemophilia and von Willebrand disease to be showcased at the ISTH 2021 Congress

LACHEN, Switzerland, July 5, 2021 /PRNewswire/ -- Octapharma announced today that new clinical and scientific findings encompassing their Haematology portfolio, including Nuwiq®, wilate®, octanate® and octanine®F, will be presented at the upcoming International Society on Thrombosis and Haemostas...

2021-07-05 19:30 3516

1 ... 339 340 341342343 344